Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
White House says popular weight-loss drug Ozempic subject to Medicare talks
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate, but if they don’t, they face fines or the possible end of Medicare reimbursements.
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned.
Novo Nordisk shares pop on early-stage weight loss drug trial results
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.
Novo Nordisk amycretin data helps rebut concerns, says BofA
After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial,
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Ozempic maker Novo Nordisk failed to disclose millions it paid to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...